-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis --

-- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients --

-- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals --

-- Bempikibart demonstrated a favorable PK, PD and ADA profile --

-- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 --

-- Q32 Bio to host conference call and webcast today, July 13, 2026, at 8:00 a.m. E.T., featuring alopecia areata key opinion leader (KOL) Arash Mostaghimi, MD, MPA, MPH --

WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.